Salvage Lung Resection after Immunotherapy is Feasible and Safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage Lung Resection after Immunotherapy is Feasible and Safe. JTCVS Open 2024, 20: 141-150. DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patientsMedicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery
Nogueira L, Boffa D, Jemal A, Han X, Yabroff K. Medicaid Expansion Under the Affordable Care Act and Early Mortality Following Lung Cancer Surgery. JAMA Network Open 2024, 7: e2351529. PMID: 38214932, PMCID: PMC10787311, DOI: 10.1001/jamanetworkopen.2023.51529.Peer-Reviewed Original ResearchConceptsMedicaid expansion statusNon-small cell lung cancerMedicaid expansion statesMedicaid expansionSurgical resection of non-small cell lung cancerResection of non-small cell lung cancerDifference-in-differencesExpansion statesPatients' state of residenceNonexpansion statesCohort studyAssociation of Medicaid expansionExpansion statusPostoperative mortalityDifference-in-differences analysisStudy population characteristicsState of residenceAffordable Care ActHealth insurance coverageCohort study of patientsSurgical resectionEarly mortalityMain OutcomesAssociated with declinesCancer outcomes